2289 — Charmacy Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$1.11bn
- HK$1.10bn
- CNY4.40bn
- 17
- 70
- 47
- 38
Annual income statement for Charmacy Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | CAS | CAS | CAS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3,493 | 3,992 | 3,794 | 4,175 | 4,404 |
| Cost of Revenue | |||||
| Gross Profit | 213 | 230 | 225 | 262 | 283 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3,438 | 3,940 | 3,761 | 4,054 | 4,337 |
| Operating Profit | 54.4 | 51.8 | 32.4 | 122 | 66.2 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 55 | 54.7 | 33 | 122 | 67.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.372 | 0.375 | 0.213 | 0.407 | 0.506 |
| Dividends per Share |